Small-Cap Momentum Watch: Upcoming Catalysts for July 13–17
7/12/20267 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies with Material Events This Week:
● VYGR – Will present a late-breaking poster on VY1706, its investigational BBB-crossing AAV gene therapy targeting tau in Alzheimer’s disease, at AAIC 2026 in London, July 12–15. The poster is scheduled for July 13 from 7:30 a.m.–4:15 p.m. GMT and follows recent FDA IND clearance, with clinical dosing expected to begin in the second half of 2026.
● LGVN – Will present additional Phase 2a data for laromestrocel in mild Alzheimer’s disease at AAIC 2026 in London and online, July 12–15. The poster presentation is scheduled for July 13 from 7:30 a.m.–4:15 p.m. BST.
● PDC – CEO Patrick Gruhn will present and take investor questions at the Emerging Growth Conference on July 15 at 12:35 p.m. ET.
● IGC – Will showcase its artificial intelligence portfolio across seven scientific presentations at AAIC 2026, taking place July 12–15 in London.
● CRVO – Will participate in five AAIC presentations, including four focused on neflamapimod in dementia with Lewy bodies. Presentations will cover MRI-measured basal forebrain atrophy, drug exposure-response relationships, the first clinical data for an 80 mg twice-daily dose, and development of a goal-based outcome measure. Sessions are scheduled across July 13–15 at AAIC 2026 in London.
● ZENA – Will exhibit ZenaDrone public-safety and first-responder drone solutions at APSCON Unmanned 2026 in Fort Lauderdale, July 15–17. The company will also present at the Qualified Capital Investments Tech Movers Event in Miami on July 15, discussing Drone-as-a-Service revenue growth and its defense drone strategy.
● ABOS – Will present one oral and two poster studies at AAIC 2026 in London, July 12–15, highlighting next-generation Alzheimer’s therapies using enhanced brain delivery technology and patient-reported insights from the ALTITUDE-AD trial. Poster sessions are scheduled for July 13 and July 14.
● SLBT – Its technology licensor will present preclinical data on intracranial gamma delta T-cell therapy for glioblastoma at the 20th World Congress of Basic and Clinical Pharmacology, taking place July 12–17 in Melbourne, Australia. The company has also submitted an FDA Orphan Drug Designation request for the same therapy.
● PALI – Management will attend the Leerink Partners Therapeutics Forum in Boston, July 14–15, holding one-on-one meetings with institutional investors to discuss PALI-2108, its inflammatory bowel disease strategy, and upcoming milestones.
● SRXH – Will host a virtual fireside chat on July 14 at 10:30 a.m. ET to discuss recent developments, the completed EMJX acquisition, and its long-term asset-management strategy.
● DARE – Will participate in a Virtual Investor Closing Bell event on July 14 at 4:00 p.m. ET. Management will discuss the recent launch of FloraSync LF5, commercialization priorities, pipeline milestones, capital allocation, and long-term growth plans, followed by live Q&A.
● VERU – Will present at the 4th Annual Obesity & Weight Loss Drug Development Summit in Boston, July 14–16. A pre-conference workshop on regulatory endpoints is scheduled for July 14 at 1:30 p.m. ET, followed by a presentation on combining GLP-1 therapies with SARMs to reduce muscle loss in older patients on July 15 at 4:20 p.m. ET.
● NUWE – Will participate in the KidneyBee Summit 2026, taking place July 14–16 in Aurora, Colorado, where it will highlight the Aquadex SmartFlow System for precise fluid management in pediatric patients with acute kidney injury, cardiorenal conditions, and fluid overload.
● AQST – Management will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host one-on-one investor meetings on July 14.
● FATE – Will participate in the Leerink Partners Therapeutics Forum in Boston on July 14–15.
● OCGN – Will participate in the OIS Retina Innovation Summit in Montreal on July 14, including a panel on regenerative approaches in retinal disease. The company will also present one-year Phase 2 OCU410 ArMaDa results and Phase 1/2 imaging and safety data at the ASRS Annual Meeting on July 17.
● IBIO – Management will attend the Leerink Partners Therapeutics Forum: I&I and Metabolism in Boston on July 14–15, holding one-on-one investor meetings.
● APM – Will present DiamiR biomarker technologies at AAIC 2026 in London and online, July 11–15. A poster on automated APOE genotyping directly from blood and buccal specimens without DNA isolation is scheduled for July 14 from 7:30 a.m.–4:15 p.m. BST.
● ACIU – Will present three studies at AAIC 2026, including an oral presentation on its first-in-class TDP-43 PET tracer on July 15 from 8:00–8:45 a.m. BST and a poster on an alpha-synuclein aggregation inhibitor on July 14. The presentations also highlight its NLRP3 inhibitor and broader Morphomer-based neurodegeneration platform.
● NAGE – CEO Rob Fried will participate in a virtual fireside chat on July 15 at 8:00 a.m. PDT, discussing its pharmaceutical program for rare genetic and aging-related diseases, NAD+ science, and recent business developments, followed by live Q&A.
● MVIS – Management will present at the Emerging Growth Virtual Conference on July 15 at 1:10 p.m. ET, with a live webcast and archived replay available through the company’s investor relations site.
● OKUR – Will host a virtual KOL event on July 15 at 11:00 a.m. ET focused on PI3Kα selectivity and its structure-based approach to developing allosteric pan-mutant PI3Kα inhibitors.
● VYNE – Shareholders will vote on the proposed merger with Yarrow Bioscience at a special meeting on July 16 at 10:00 a.m. ET. A merger-contingent special cash dividend is estimated at $0.38 per share, payable to holders of record on July 22, with the merger expected to close around July 24, subject to approval and other conditions.
● BAER – Management will present at the RedChip Vertical Economy Virtual Investor Conference: The Race to Dominate the Skies on July 16 at 2:30 p.m. ET.
● CRDL – Will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16 at 12:20 p.m. ET.
● KTTA – Management will participate in the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, including investor meetings and discussions focused on PAS-004 and neurofibromatosis type 1.
● LCTX – CEO Brian Culley will participate in a fireside chat at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit in Boston on July 16.
● STIM – Will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, including a panel titled “Commercializing the Next Wave of Novel Neuropsychiatric Drugs” and one-on-one investor meetings.
● VTIX – Will present at Emerging Growth Conference 94 on July 16 at 10:15 a.m. ET, followed by Q&A and investor meetings. Management will discuss consumer XR growth, defense simulation deployments, recent contracts, and fiscal 2026 results, including higher sales, improved gross profit, margin expansion, and lower operating expenses.
● ENVB – CEO Joseph Tucker will participate in a neuropsychiatry fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16 from 12:30–12:55 p.m. ET.
● NEPH – Will host a virtual investor event titled “Beyond Filtration: The Nephros Model in Action” on July 16, highlighting its scalable water-safety model, field partnerships, education initiatives, and broader customer value proposition.
● AUUD – Will integrate its Discovr Radio artist-promotion platform throughout CAMP Toronto, July 16–19, marking its first major on-site activation under its partnership with Beatcave.
● HYPD – Will participate in the Hyperliquid Summit in New York on July 16.
● MLSS – Will showcase its technology at the American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, while continuing to advance commercialization initiatives and expected revenue growth.
● SITC – Sold its interest in The Pike Outlets for $50 million in cash, generating approximately $46.5 million in net proceeds. The board also declared a $1.00 special cash distribution, payable July 31 to shareholders of record on July 17. Because the dividend exceeds 25% of the share price, due-bill trading rules will apply through the payment date.
● KLRS – Will present first-in-human Phase 1a data for TH103, a dual-targeting VEGF/HSPG biologic for neovascular AMD, at the ASRS 2026 Annual Meeting in Montreal on July 17 at 8:00 a.m. ET. Its Phase 1b/2 study remains actively enrolling, with initial data expected in the first half of 2027.
● NIXX – Entered into an amended binding LOI with Tachyon 9 for a proposed business combination creating a publicly traded AI and high-performance computing infrastructure platform. The transaction includes rights tied to a proposed 620-acre North Dakota campus targeting up to 1 GW of power, plus approximately $64 million in data-center equipment. Tachyon is preliminarily valued at about $1 billion, with its shareholders expected to own at least 90% of the combined company. The 30-day exclusivity period is expected to run through approximately July 15, with a potential $75 million PIPE financing also contemplated.
● NCPL – Entered into a non-binding LOI for a proposed acquisition of substantially all assets and liabilities of residential mortgage bank Resmac through a newly formed subsidiary. The proposed $5 million transaction would be paid entirely in preferred stock, with no cash or common-stock consideration. Due diligence is expected to run through approximately July 14–15, while exclusivity extends to late August. Closing remains subject to regulatory approvals, lender consents, licensing, board approval, and definitive agreements.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.